# Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya

> **NCT00427297** · PHASE3 · TERMINATED · sponsor: **University of Washington** · enrollment: 34 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)
- **DRUG:** d4T/3TC/NVP (stavudine/lamivudine/nevirapine)
- **DRUG:** AZT/3TC/ABC (zidovudine/lamivudine/abacavir)
- **DRUG:** d4T/3TC/ABC (stavudine/lamivudine/abacavir)
- **DRUG:** ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)
- **DRUG:** ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)
- **DRUG:** ABC/3TC/NVP (abacavir/lamivudine/nevirapine)

## Key facts

- **NCT ID:** NCT00427297
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2009-05
- **Final completion:** 2009-12
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** There is no longer equipoise. DSMB recommended termination.
- **Last updated:** 2018-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427297, "Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00427297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*